Mylan shareholders reject executive pay plan
Shareholders of beleaguered Netherlands-incorporated drugmaker Mylan (Nasdaq: MYL) voted against the company's executive pay policy but re-elected the board at its annual meeting on Thursday, despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment.
The Mylan vote signals deep dissension over the $98 million in compensation awarded to former chief executive Robert Coury, who is now Mylan’s executive chairman. Current Mylan CEO Heather Bresch was also awarded $13.8 million in total compensation and a larger equity award in 2016.
The annual meeting was held in Amsterdam, where the company has been headquartered since 2015. It was sparsely attended, with around the same number of attendees from the company as those in the audience, according to Reuters.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze